Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Rhea-AI Summary

Minerva Neurosciences (Nasdaq: NERV) announced it will release its fiscal year 2022 financial results and business updates on March 8, 2023. A conference call will follow on the same day at 8:30 a.m. Eastern Time. The company focuses on developing therapies for central nervous system disorders. Its product candidates include roluperidone for schizophrenia and MIN-301, currently in pre-clinical development for Parkinson’s disease. Details of the live webcast and subsequent archived session are available on the company’s website.

Positive

• Company set to announce fiscal year 2022 financial results on March 8, 2023.
• Conference call scheduled to provide insights into business updates.

Negative

• None.

Management to Host Conference Call

BURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release fiscal year 2022 financial results and business updates on Wednesday, March 8, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates.

The live conference call may be accessed here and on the Company’s website under Events and Presentations.

The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences

Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (MIN-101), for negative symptoms of schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. For more information, please visit our website.

For more information:

Investor inquiries:                                                 
Fred Ahlholm                                                        
CFO, Minerva Neurosciences                                         
info@minervaneurosciences.com                 

Media Inquiries:
Helen Shik
Principal, Shik Communications LLC
helen@shikcommunications.com

 

FAQ

What date will Minerva Neurosciences release its fiscal year 2022 financial results?

Minerva Neurosciences will release its fiscal year 2022 financial results on March 8, 2023.

When is the conference call for Minerva Neurosciences' financial results?

The conference call for Minerva Neurosciences' financial results is scheduled for March 8, 2023, at 8:30 a.m. Eastern Time.

What is the focus of Minerva Neurosciences?

Minerva Neurosciences focuses on developing therapies for central nervous system disorders.

What are the key product candidates of Minerva Neurosciences?

Minerva's key product candidates include roluperidone for schizophrenia and MIN-301 for Parkinson’s disease.